Treatment of Infections Caused by Metronidazole-Resistant Trichomonas vaginalis
AUTOR(ES)
Cudmore, Sarah L.
FONTE
American Society for Microbiology
RESUMO
Infections with the sexually transmitted protozoan Trichomonas vaginalis are usually treated with metronidazole, a 5-nitroimidazole drug derived from the antibiotic azomycin. Metronidazole treatment is generally efficient in eliminating T. vaginalis infection and has a low risk of serious side effects. However, studies have shown that at least 5% of clinical cases of trichomoniasis are caused by parasites resistant to the drug. The lack of approved alternative therapies for T. vaginalis treatment means that higher and sometimes toxic doses of metronidazole are the only option for patients with resistant disease. Clearly, studies of the treatment and prevention of refractory trichomoniasis are essential. This review describes the mechanisms of metronidazole resistance in T. vaginalis and provides a summary of trichomonicidal and vaccine candidate drugs.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=523556Documentos Relacionados
- Metronidazole-resistant Trichomonas vaginalis.
- Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis.
- In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis.
- Growth inhibition of metronidazole-susceptible and metronidazole-resistant strains of Gardnerella vaginalis by Lactobacilli in vitro.
- Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains.
